Table of Contents
ISRN Obesity
Volume 2013 (2013), Article ID 751401, 4 pages
http://dx.doi.org/10.1155/2013/751401
Research Article

Effect of Ghrelin on Hepatic IGF-Binding Protein-1 Production

School of Health, Nursing and Midwifery, University of the West of Scotland, Paisley Campus, Paisley PA1 2BE, UK

Received 28 November 2012; Accepted 1 January 2013

Academic Editors: E. K. Naderali, S. J. Pintauro, and J. Saleh

Copyright © 2013 Moira S. Lewitt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Firth and R. C. Baxter, “Cellular actions of the insulin-like growth factor binding proteins,” Endocrine Reviews, vol. 23, no. 6, pp. 824–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Yki-Järvinen, S. Makimattila, T. Utriainen, and E. M. Rutanen, “Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 11, pp. 3227–3232, 1995. View at Google Scholar · View at Scopus
  3. M. S. Lewitt, A. Hilding, C. G. Östenson, S. Efendic, K. Brismar, and K. Hall, “Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men,” Diabetologia, vol. 51, no. 7, pp. 1135–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Conover, P. D. K. Lee, J. A. Kanaley, J. T. Clarkson, and M. D. Jensen, “Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans,” Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 6, pp. 1355–1360, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. C. H. Lang, G. J. Nystrom, and R. A. Frost, “Regulation of IGF binding protein-1 in Hep G2 cells by cytokines and reactive oxygen species,” American Journal of Physiology, vol. 276, no. 3, pp. G719–G727, 1999. View at Google Scholar · View at Scopus
  6. C. Höybye, J. Frystyk, and M. Thorén, “The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome,” Growth Hormone and IGF Research, vol. 13, no. 5, pp. 269–274, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. D. E. Cummings, K. Clement, J. Q. Purnell et al., “Elevated plasma ghrelin levels in Prader-Willi syndrome,” Nature Medicine, vol. 8, no. 7, pp. 643–644, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Delparigi, M. Tschöp, M. L. Heiman et al., “High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 12, pp. 5461–5464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Tschöp, C. Weyer, P. A. Tataranni, V. Devanarayan, E. Ravussin, and M. L. Heiman, “Circulating ghrelin levels are decreased in human obesity,” Diabetes, vol. 50, no. 4, pp. 707–709, 2001. View at Google Scholar · View at Scopus
  10. T. Shiiya, M. Nakazato, M. Mizuta et al., “Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 240–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Lewitt and R. C. Baxter, “Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?” Molecular and Cellular Endocrinology, vol. 79, no. 1–3, pp. C147–C152, 1991. View at Google Scholar · View at Scopus
  12. P. J. Delhanty and A. J. van der Lely, “Ghrelin and glucose homeostasis,” Peptides, vol. 32, no. 11, pp. 2309–2318, 2011. View at Publisher · View at Google Scholar
  13. T. J. Zhao, G. Liang, R. L. Li et al., “Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7467–7472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Sun, N. F. Butte, J. M. Garcia, and R. G. Smith, “Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance,” Endocrinology, vol. 149, no. 2, pp. 843–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Verhulst and I. Depoortere, “Ghrelin's second life: from appetite stimulator to glucose regulator,” World Journal of Gastroenterology, vol. 18, no. 25, pp. 3183–3195, 2012. View at Publisher · View at Google Scholar
  16. M. S. Lewitt, “Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase,” Biochemical and Biophysical Research Communications, vol. 282, no. 5, pp. 1126–1131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Murata, Y. Okimura, K. Iida et al., “Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells,” The Journal of Biological Chemistry, vol. 277, no. 7, pp. 5667–5674, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Gauna, P. J. D. Delhanty, L. J. Hofland et al., “Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 2, pp. 1055–1060, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Barazzoni, A. Bosutti, M. Stebel et al., “Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle,” American Journal of Physiology, vol. 288, no. 1, pp. E228–E235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Barazzoni, M. Zanetti, M. R. Cattin et al., “Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rats,” Obesity, vol. 15, no. 11, pp. 2614–2623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. C. Heijboer, A. M. van den Hoek, E. T. Parlevliet et al., “Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice,” Diabetologia, vol. 49, no. 4, pp. 732–738, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Xue and B. B. Kahn, “AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues,” Journal of Physiology, vol. 574, no. 1, pp. 73–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Westwood, “Role of insulin-like growth factor binding protein 1 in human pregnancy,” Reviews of Reproduction, vol. 4, no. 3, pp. 160–167, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Tawadros, L. A. Salamonsen, E. Dimitriadis, and C. Chen, “Facilitation of decidualization by locally produced ghrelin in the human endometrium,” Molecular Human Reproduction, vol. 13, no. 7, pp. 483–489, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. S. Lewitt, A. Hilding, K. Brismar, S. Efendic, C. G. Östenson, and K. Hall, “IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women,” European Journal of Endocrinology, vol. 163, no. 2, pp. 233–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. N. Rajpathak, M. He, Q. Sun et al., “Insulin-like growth factor axis and risk of type 2 diabetes in women,” Diabetes, vol. 61, no. 9, pp. 2248–2254, 2012. View at Publisher · View at Google Scholar
  27. O. Ukkola, S. M. Pöykkö, and Y. A. Kesäniemi, “Low plasma ghrelin concentration is an indicator of the metabolic syndrome,” Annals of Medicine, vol. 38, no. 4, pp. 274–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Ikezaki, H. Hosoda, K. Ito et al., “Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents,” Diabetes, vol. 51, no. 12, pp. 3408–3411, 2002. View at Google Scholar · View at Scopus
  29. A. Katsuki, H. Urakawa, E. C. Gabazza et al., “Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus,” European Journal of Endocrinology, vol. 151, no. 5, pp. 573–577, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. M. Pöykkö, E. Kellokoski, S. Hörkkö, H. Kauma, Y. A. Kesäniemi, and O. Ukkola, “Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes,” Diabetes, vol. 52, no. 10, pp. 2546–2553, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. A. P. Goldstone, M. Patterson, N. Kalingag et al., “Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY 3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2681–2690, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. L. J. Murphy, “The role of the insulin-like growth factors and their binding proteins in glucose homeostasis,” Experimental Diabesity Research, vol. 4, no. 4, pp. 213–224, 2003. View at Google Scholar · View at Scopus
  33. M. Tschop, D. L. Smiley, and M. L. Heiman, “Ghrelin induces adiposity in rodents,” Nature, vol. 407, no. 6806, pp. 908–913, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Patterson, S. R. Bloom, and J. V. Gardiner, “Ghrelin and appetite control in humans—potential application in the treatment of obesity,” Peptides, vol. 32, no. 11, pp. 2290–2294, 2011. View at Publisher · View at Google Scholar